FACTORS DETERMINING BONE MINERAL DENSITY LOSS IN CHRONIC HEPATITIS B PATIENTS: IS TENOFOVIR DISOPROXIL FUMARATE THE MAIN CULPRIT?

被引：3
|
作者：
Gill, U. S. [1 ]
Al-Shamma, S. [1 ]
Burke, K. [1 ]
Ross, V. [1 ]
Kooner, P. [1 ]
Marley, R. [1 ]
Foster, G. R. [1 ]
Kennedy, P. T. F. [1 ]
机构：
[1] Barts & London Queen Marys Sch Med & Dent, London, England
来源：
JOURNAL OF HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
10.1016/S0168-8278(11)60715-0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
713
引用
收藏
页码：S286 / S286
页数：1
相关论文
共 50 条
  • [11] Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients With Lamivudine-Resistant Chronic Hepatitis B
    Fung, Scott
    Kwan, Peter
    Fabri, Milotka
    Horban, Andrzej
    Pelemis, Mijomir
    Hann, Hie-Won
    Gurel, Selim
    Caruntu, Florin A.
    Flaherty, John F.
    Massetto, Benedetta
    Dinh, Phillip
    Corsa, Amoreena
    Subramanian, G. Mani
    McHutchison, John G.
    Husa, Petr
    Gane, Edward
    GASTROENTEROLOGY, 2014, 146 (04) : 980 - U521
  • [12] Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B
    Cui, Guangying
    Xu, Xuejun
    Diao, Hongyan
    SCIENTIFIC REPORTS, 2015, 5
  • [13] Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection
    Wai-Kay Seto
    Man-Fung Yuen
    James Fung
    Ching-Lung Lai
    Hepatology International, 2013, 7 : 327 - 334
  • [14] Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B
    Guangying Cui
    Xuejun Xu
    Hongyan Diao
    Scientific Reports, 5
  • [15] Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection
    Seto, Wai-Kay
    Yuen, Man-Fung
    Fung, James
    Lai, Ching-Lung
    HEPATOLOGY INTERNATIONAL, 2013, 7 (02) : 327 - 334
  • [16] Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection
    Jones, J.
    Colquitt, J.
    Shepherd, J.
    Harris, P.
    Cooper, K.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 23 - 29
  • [17] IMPROVEMENT OF BONE MINERAL DENSITY AND MARKERS OF PROXIMAL RENAL TUBULAR FUNCTION IN 12 WEEKS IN CHRONIC HEPATITIS B PATIENTS SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE TO TENOFOVIR ALAFENAMIDE
    Fong, Tse-Ling
    Lee, Brian T.
    Tien, Andy
    Le, Justin
    Ahn, Aiden
    Kim, Carolina
    Chang, Mimi
    Bae, Ho
    GASTROENTEROLOGY, 2018, 154 (06) : S1133 - S1134
  • [18] Long-term renal and bone safety of tenofovir disoproxil fumarate in chronic hepatitis B patients
    Butt, N.
    Rai, L.
    Hussain, R.
    Khemani, H.
    Ali, S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 84 - 84
  • [19] Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
    Hong, Hyeyeon
    Choi, Won-Mook
    Lee, Danbi
    Shim, Ju Hyun
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    Choi, Jonggi
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (01) : 49 - 63
  • [20] Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
    Yim, Hyung Joon
    Kim, Ji Hoon
    Cho, Yong Kyun
    Kweon, Young Oh
    Cho, Hyun Chin
    Hwang, Jae Seok
    Lee, Changhyeong
    Koh, Moon Soo
    Baek, Yang-Hyun
    Park, Young-Min
    Lee, Jeong-Hoon
    Kim, Seung Up
    Kang, Min-Kyu
    Park, Neung Hwa
    Lee, June Sung
    Chon, Young Eun
    Cheon, Gab Jin
    Chae, Hee Bok
    Sohn, Joo Hyun
    Lim, Young-Suk
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 3263 - 3274
12345